



*Journal of Psychopharmacology*  
2016, Vol. 30(12) 1209–1210  
© The Author(s) 2016  
Reprints and permissions:  
sagepub.co.uk/journalsPermissions.nav  
DOI: 10.1177/0269881116675771  
jop.sagepub.com

# **Psilocybin for depression and anxiety associated with life-threatening illnesses**

**John D McCorvy, Reid HJ Olsen and Bryan L Roth**

Life-threatening and terminal illnesses are accompanied by substantial stressors that encumber both patients and their families. Faced with a life-threatening diagnosis such as late-stage cancer, these factors can compound the existential crisis of impending mortality and produce or exacerbate major depressive and anxiety symptoms (Silverstone, 1990; Vergo et al., 2016). Addressing depression and anxiety in the unique context of life-threatening illnesses has been a significant problem for palliative psychiatric care. In this regard, two recent studies suggest that the one-time use of the naturally derived psychoactive compound psilocybin could have the potential to alleviate these symptoms for up to six months.

Two independent studies by Griffiths et al. (2016) and Ross et al. (2016) demonstrate that psilocybin, a serotonergic psychedelic, can produce a rapid and clinically significant decrease in the symptoms of depression and anxiety, which can persist for up to six months. Each study utilized a double-blind design and employed different active control compounds to address design-based confounds associated with the use of a psychoactive drug. Griffiths et al. (2016) used a low dose (1–3 mg) of psilocybin, while Ross et al. (2016) selected niacin. It is worth noting that the placebo effect is a major confound in the development of novel antidepressant drugs, as placebos can produce antidepressant effects in 30–40% of individuals (Papakostas et al., 2016). Psilocybin treatment was associated with statistically significant antidepressant and anxiolytic effects in both studies. The use of two separate control compounds (including a subclinical dose of psilocybin as control) minimizes the potential outcome that the effects are due to placebo rather than an active drug effect.

Additionally, these studies utilized a crossover design, where patients receiving placebo for the first administration were given psilocybin in the second half of the study. When patients in this latter group were given psilocybin, they also exhibited marked reductions in depression and anxiety-related symptoms beyond that which may have occurred following administration of the control compounds. Together with their larger sample of participants compared with prior trials (51 and 29, respectively), these studies provide support for definitive trials designed to test the hypothesis that psilocybin may have therapeutic effects with what appear to be minimal side-effects.

A prior open-label study also showed apparent efficacy of psilocybin in treatment-resistant depression (Carhart-Harris et al., 2016), and although other studies have suggested a role for psychedelics such as psilocybin and lysergic acid diethylamide (LSD) as adjuncts to psychotherapy (Carhart-Harris et al., 2012; Gasser et al., 2014; Grob et al., 2011), these prior studies have

been criticized for their small sample size and open-label design. The current studies represents a significant advance over these prior studies by virtue of larger sample sizes and the use of comparator compounds as controls.

Serotonin selective reuptake inhibitors (SSRIs) and other antidepressants are thought to exert many of their actions, in part, by augmenting the concentration of serotonin at the neuronal synapse. Indeed, direct activation of serotonergic nuclei in the dorsal raphe can produce antidepressant-like effects in animal models (Urban et al., 2016). The antidepressant effects of SSRIs and other conventional tricyclic antidepressants, however, require at least three to six weeks to achieve clinical efficacy (Frazer and Benmansour, 2002), which may not be optimal for individuals with terminal illness.

Although SSRIs and psilocybin presumably both work via modulating central nervous serotonin, psilocin, the active hydroxy metabolite of psilocybin, directly activates serotonin receptors, including 5-HT<sub>2A</sub> receptors located on prefrontal cortical neurons (Willins et al., 1997). Elevated cortical 5-HT<sub>2A</sub> receptor expression has been implicated in depression-related suicide (Pandey, 2013; Pandey et al., 2002), and SSRIs have been reported to reduce cortical 5-HT<sub>2A</sub> receptor expression (Yamauchi et al., 2006) via a process termed receptor downregulation. Considering that both 5-HT<sub>2A</sub> antagonists and agonists have been found to induce 5-HT<sub>2A</sub> downregulation (Yadav et al., 2011), and that several newer generation antidepressants such as mirtazepine (Nutt, 1998) possess 5-HT<sub>2A</sub> antagonist activity, it is conceivable that psilocin may possess such sustained antidepressant effects with one-time use via downregulating serotonin receptors, although further studies are needed to test this hypothesis directly. It should be noted, though, that psilocin has actions at essentially all other serotonin receptors (<http://kidbdev.med.unc.edu/databases/kidb.php>), and its actions could be due to a

Department of Pharmacology, Division of Chemical Biology and Medicinal Chemistry and the National Institute of Mental Health Psychoactive Drug Screening Program, University of North Carolina Chapel Hill Medical School, Chapel Hill, NC, USA

## **Corresponding author:**

Bryan L Roth, Department of Pharmacology, Division of Chemical Biology and Medicinal Chemistry and the National Institute of Mental Health Psychoactive Drug Screening Program, University of North Carolina Chapel Hill Medical School, Chapel Hill, NC 27599, USA.  
Email: [bryan\\_roth@med.unc.edu](mailto:bryan_roth@med.unc.edu)

combination of actions at many serotonin receptors in addition to its agonist actions at 5-HT<sub>2A</sub> receptors.

Over the past 50 years, the use of psychedelic drugs such as psilocybin and LSD as potential therapeutics has remained controversial (Nichols, 2016). The Griffiths et al. (2016) and Ross et al. (2016) studies, as well as previous studies (Griffiths et al., 2006), suggest that the mystical experience stemming from psilocybin sessions may be an integral part of the antidepressant process. Given the complex pharmacology of these compounds, however, it would be essential to extend these findings, for instance by attempting to abrogate the hallucinatory actions via pretreatment with a 5-HT<sub>2A</sub>-selective antagonist. Alternatively, more selective 5-HT<sub>2A</sub> agonists exist (e.g., 2,5-dimethoxy-4-iodoamphetamine), and it would be interesting to see if they have similar apparent antidepressant actions. This is particularly relevant given the recent finding that the antidepressant actions of ketamine may be due to metabolites, which lack the NMDA-like pharmacology associated with the parent compound (Zanos et al., 2016).

Nonetheless, the findings of Griffiths et al. (2016) and Ross et al. (2016)—that one-time use of psilocybin can produce clinically relevant and apparently long-lasting effects on depressive and anxious symptoms—are remarkable, and they underscore the potential for psilocybin as an alternative to first-line antidepressants.

### Declaration of conflicting interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

### Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Work in the authors' lab is supported by the National Institutes of Health. RHJO was supported by F31NS093917.

### References

- Carhart-Harris RL, Bolstridge M, Rucker J, et al. (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. *Lancet Psychiatry* 3: 619–627.
- Carhart-Harris RL, Leech R, Williams TM, et al. (2012) Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. *Br J Psychiatry* 200: 238–244.
- Frazer A and Benmansour S (2002) Delayed pharmacological effects of antidepressants. *Mol Psychiatry* 7: S23–28.
- Gasser P, Holstein D, Michel Y, et al. (2014) Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. *J Nerv Ment Dis* 202: 513–520.
- Griffiths RR, Johnson MW, Carducci MA, et al. (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. *J Psychopharmacol* 30: 1181–1197.
- Griffiths RR, Richards WA, McCann U, et al. (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. *Psychopharmacology* 187: 268–283.
- Grob CS, Danforth AL, Chopra GS, et al. (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. *Arch Gen Psychiatry* 68: 71–78.
- Nichols DE (2016) Psychedelics. *Pharmacol Rev* 68: 264–355.
- Nutt DJ (1998) Efficacy of mirtazapine in clinically relevant subgroups of depressed patients. *Depress Anxiety* 7: 7–10.
- Pandey GN (2013) Biological basis of suicide and suicidal behavior. *Bipolar Disord* 15: 524–541.
- Pandey GN, Dwivedi Y, Rizavi HS, et al. (2002) Higher expression of serotonin 5-HT<sub>2A</sub> receptors in the postmortem brains of teenage suicide victims. *Am J Psychiatry* 159: 419–429.
- Papakostas GI, Martinson MA, Fava M, et al. (2016) Demographic variables, design characteristics, and effect sizes of randomized, placebo-controlled, monotherapy trials of major depressive disorder and bipolar depression. *J Clin Psychiatry* 77: e619–624.
- Ross S, Bossis A, Guss J, et al. (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. *J Psychopharmacol* 30: 1165–1180.
- Silverstone PH (1990) Depression increases mortality and morbidity in acute life-threatening medical illness. *J Psychosom Res* 34: 651–657.
- Urban DJ, Zhu H, Marcinkiewicz CA, et al. (2016) Elucidation of the behavioral program and neuronal network encoded by dorsal raphe serotonergic neurons. *Neuropsychopharmacology* 41: 1404–1415.
- Vergo MT, Whyman J, Li Z, et al. (2016) Assessing preparatory grief in advanced cancer patients as an independent predictor of distress in an American population. *J Palliat Med*. Epub ahead of print 1 Sep 2016.
- Willins DL, Deutch AY and Roth BL (1997) Serotonin 5-HT<sub>2A</sub> receptors are expressed on pyramidal cells and interneurons in the rat cortex. *Synapse* 27: 79–82.
- Yadav PN, Kroeze WK, Farrell MS, et al. (2011) Antagonist functional selectivity: 5-HT<sub>2A</sub> serotonin receptor antagonists differentially regulate 5-HT<sub>2A</sub> receptor protein level in vivo. *J Pharmacol Exp Ther* 339: 99–105.
- Yamauchi M, Miyara T, Matsushima T, et al. (2006) Desensitization of 5-HT<sub>2A</sub> receptor function by chronic administration of selective serotonin reuptake inhibitors. *Brain Res* 1067: 164–169.
- Zanos P, Moaddel R, Morris PJ, et al. (2016) NMDAR inhibition-independent antidepressant actions of ketamine metabolites. *Nature* 533: 481–486.